Shots:

• Mundipharma to get exclusive rights to distribute- market and commercialize Tuznue in selected EU countries following marketing authorization- including France- Spain- Norway- Sweden- Denmark- Finland- Portugal- Switzerland and Austria
• The EMA approval of Tuznue is based on positive results confirming it as a biosimilar to Herceptin in terms of clinical response and PK with a comparable safety profile to the range previously observed in other trastuzumab biosimilar trials
• Tuznue is a mAb and a biosimilar to Roche’s Herceptin- that interferes with the human epidermal growth factor receptor 2 (HER2) targeted to treat patients with HER2-overexpressing breast cancer- HER2-overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma

Click here to read full press release/ article | Ref: Mundipharma | Image: Twitter